| GuangDong YingHao Biotech. Co.Ltd, was invested by Drangon Biotech Pharmacy Co.Ltd (USA) and SiChuan Yinghao Science and Teaching Co.Ltd. The company is a moden biotech medicine enterprise, Eagaged in produing> marketing and scientific research.Now, the products that has been produced are RH-EPO and RH-TPA. In the labcentre in USA, the scientists of the company had succeed found a new way to produce the medicine RHGM-CSF, RHIL-11, RH-BPI. These medicines have more advantage than the same medicine that we now use.In this paper, I intended to discuss the chance and the challenge the advantage and disadvantage of the company. Facing the various requirement in the medicine market, especially in the biotech medicine market, I also analysised the producion condition and the technical advantage of the company. Through comparision, anlysis, and reasoning, the paper finally gained a conclusion, that YingHao Biotech Co, Ltd. invest in the biotech item RHGM-CSF, RHIL-11 and RH-BPI is manipulable and the profit will be great. |
PDF Full Text Request